SBH
CKPT

Segall Bryant & Hamill’s Checkpoint Therapeutics CKPT Stock Holding History

Segall Bryant & Hamill’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,500
Closed -$26K – 715
2022
Q3 		$26K Hold
2,500
– – ﹤0.01% 718
2022
Q2 		$26K Hold
2,500
– – ﹤0.01% 722
2022
Q1 		$44K Buy
2,500
+1,000
+67% +$21.5K ﹤0.01% 740
2021
Q4 		$47K Hold
1,500
– – ﹤0.01% 593
2021
Q3 		$50K Buy
+1,500
New +$44.3K ﹤0.01% 778

Other funds holding CKPT

TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Segall Bryant & Hamill's CKPT Position: Q4 2022 in Review

Segall Bryant & Hamill sold out of Checkpoint Therapeutics (CKPT) in Q4 2022, closing a stake of 2,500 shares — an estimated $26K sold.

Segall Bryant & Hamill first reported a position in CKPT in Q3 2021 and held it in 5 quarters. The position peaked at $50K in Q3 2021. 40 funds tracked by Wall St. Rank hold CKPT as of Q4 2022.

  • Segall Bryant & Hamill reported no remaining Checkpoint Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Segall Bryant & Hamill sold 2,500 Checkpoint Therapeutics shares in Q4 2022, an estimated $26K.
  • Segall Bryant & Hamill first reported a position in Checkpoint Therapeutics in Q3 2021 and held it in 5 quarters.
  • Segall Bryant & Hamill's Checkpoint Therapeutics position peaked at $50K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2022.

Based on Segall Bryant & Hamill's 13F filing for Q4 2022, filed 14 Feb 2023.